Lv3
336 积分 2021-11-15 加入
514MO The efficacy and safety of ivonescimab with or without ligufalimab in combination with FOLFOXIRI as first-line (1L) treatment for metastatic colorectal cancer (mCRC)
10天前
已完结
Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial
11天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
15天前
已完结
Malignant Superior Vena Cava Syndrome: A Scoping Review
16天前
已完结
中国非小细胞肺癌放射治疗临床指南（2020版）
17天前
已完结
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
25天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
1个月前
已完结
Abstract 5655: YL252: A dual-functional PD-L1/VEGF-targeting ADC integrating immunotherapy, anti-angiogenesis, and cytotoxicity
1个月前
已关闭
Abstract 6536: A novel multi-modal PD-L1xVEGF-ADC, HX116, could be a new potent candidate treatment for pan-solid tumors
1个月前
已完结
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial
1个月前
已完结
皖公网安备34019202002308
